Skip to main content
Top
Published in: Current Hypertension Reports 5/2010

Open Access 01-10-2010

Is the Presence of Microalbuminuria a Relevant Marker of Kidney Disease?

Author: Richard J. Glassock

Published in: Current Hypertension Reports | Issue 5/2010

Login to get access

Abstract

Levels of urinary albumin excretion that are below the usual limit of detection by qualitative testing, but are above normal levels (microalbuminuria; MA), can be readily identified by simple measures, such as the urinary albumin to creatinine ratio in untimed urine samples. Such measurements, particularly when combined with assessment of estimated glomerular filtration rate (eGFR), have utility as biomarkers for enhanced risk of all-cause mortality, cardiovascular events, progressive chronic kidney disease, and end-stage renal disease in diabetic and nondiabetic subjects. However, it is controversial whether “isolated” MA (MA in the absence of a clear reduction in eGFR, urine sediment abnormalities, or structural renal disease) should be regarded as kidney disease. Such MA could also be regarded as a manifestation of a diffuse endothelial (microvascular) injury and thereby collateral kidney damage. This article reviews the current evidence concerning MA as a marker of kidney disease or kidney damage.
Literature
1.
go back to reference Svendsen PA, Oxenball B, Christiansen JS: Microalbuminuria in diabetic patients—a longitudinal study. Acta Endocrinol Suppl (Copenhagen) 1981, 242:53–54. Svendsen PA, Oxenball B, Christiansen JS: Microalbuminuria in diabetic patients—a longitudinal study. Acta Endocrinol Suppl (Copenhagen) 1981, 242:53–54.
2.
go back to reference Viberti GC, Hill RD, Jarrett RJ, et al.: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982, 1:1430–1432.CrossRefPubMed Viberti GC, Hill RD, Jarrett RJ, et al.: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982, 1:1430–1432.CrossRefPubMed
3.
go back to reference National Kidney Foundation: Kidney Disease Outcomes Quality Initiative. Clinical Practice Guidelines for Chronic Kidney Disease; Evaluation, Classification and Stratification. Am J Kidney Disease 2002, 39(Suppl 1):S1–S264. National Kidney Foundation: Kidney Disease Outcomes Quality Initiative. Clinical Practice Guidelines for Chronic Kidney Disease; Evaluation, Classification and Stratification. Am J Kidney Disease 2002, 39(Suppl 1):S1–S264.
4.
go back to reference Epstein M: Aging and the kidney. J Am Soc Neprhol 1996, 7:1106–1122. Epstein M: Aging and the kidney. J Am Soc Neprhol 1996, 7:1106–1122.
5.
6.
go back to reference Leong SO, Lui KF, Ng WY, Thai AC: The use of semi-quantitative urine test-strip (Micral test) for microalbuminuria screening in patients with diabetes mellitus. Singapore Med J 1998, 39:101–103.PubMed Leong SO, Lui KF, Ng WY, Thai AC: The use of semi-quantitative urine test-strip (Micral test) for microalbuminuria screening in patients with diabetes mellitus. Singapore Med J 1998, 39:101–103.PubMed
7.
go back to reference Sarafidis PA, Riehle J, Bogojevic Z, et al.: A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol 2009, 28:324–329.CrossRef Sarafidis PA, Riehle J, Bogojevic Z, et al.: A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol 2009, 28:324–329.CrossRef
8.
go back to reference Haraldsson B, Nystrom J, Deen WM: Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008, 88:451–487.CrossRefPubMed Haraldsson B, Nystrom J, Deen WM: Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008, 88:451–487.CrossRefPubMed
9.
go back to reference Russo LM, Sandoval RM, Campos SB, et al.: Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009, 20:489–494.CrossRefPubMed Russo LM, Sandoval RM, Campos SB, et al.: Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009, 20:489–494.CrossRefPubMed
10.
go back to reference Russo LM, Bakris GL, Comper WD: Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis 2002, 39:899–919.CrossRefPubMed Russo LM, Bakris GL, Comper WD: Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis 2002, 39:899–919.CrossRefPubMed
11.
go back to reference Bundschuh I, Jackle-Meyer I, Luneberg E, et al.: Glycation of serum albumin and its role in renal protein excretion and the development of diabetic nephropathy. Eur J Chem Clin Biochem 1992, 30:651–656. Bundschuh I, Jackle-Meyer I, Luneberg E, et al.: Glycation of serum albumin and its role in renal protein excretion and the development of diabetic nephropathy. Eur J Chem Clin Biochem 1992, 30:651–656.
12.
go back to reference •• James MT, Hemmelgarn BR, Tonelli M: Early recognition and prevention of chronic kidney disease. Lancet 2010, 375:1296–1309. This is a seminal review article that summarizes knowledge regarding detection and prevention of chronic kidney disease in a succinct and readable fashion.CrossRefPubMed •• James MT, Hemmelgarn BR, Tonelli M: Early recognition and prevention of chronic kidney disease. Lancet 2010, 375:1296–1309. This is a seminal review article that summarizes knowledge regarding detection and prevention of chronic kidney disease in a succinct and readable fashion.CrossRefPubMed
13.
go back to reference • Hallan SI, Ritz E, Lydersen S, et al.: Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009, 20:1069–1077. This is an excellent article that clearly shows the interactions between eGFR and albuminuria in determining risk for progressive kidney disease.CrossRefPubMed • Hallan SI, Ritz E, Lydersen S, et al.: Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009, 20:1069–1077. This is an excellent article that clearly shows the interactions between eGFR and albuminuria in determining risk for progressive kidney disease.CrossRefPubMed
14.
go back to reference •• Hemmelgarn BR, Manns BJ, Lloyd A, et al.; Alberta Kidney Disease Network: Relation between kidney function, proteinuria and adverse outcomes. JAMA 2010, 301:423–429. This seminal article describes the relationship between eGFR and albuminuria or proteinuria and risk for cardiovascular events and progressive kidney disease.CrossRef •• Hemmelgarn BR, Manns BJ, Lloyd A, et al.; Alberta Kidney Disease Network: Relation between kidney function, proteinuria and adverse outcomes. JAMA 2010, 301:423–429. This seminal article describes the relationship between eGFR and albuminuria or proteinuria and risk for cardiovascular events and progressive kidney disease.CrossRef
15.
go back to reference van der Velde M, de Jong PE, Gansevoort RT: Comparison of the yield of differing screening approaches to detect chronic kidney disease. Nephrol Dial Transplant 2010 (Epub ahead of print). van der Velde M, de Jong PE, Gansevoort RT: Comparison of the yield of differing screening approaches to detect chronic kidney disease. Nephrol Dial Transplant 2010 (Epub ahead of print).
16.
go back to reference Coresh J, Selvin E, Stevens LA, et al.: Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2018–2047.CrossRef Coresh J, Selvin E, Stevens LA, et al.: Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2018–2047.CrossRef
17.
go back to reference •• Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073–2081. This landmark study involved a very large collection of databases and meta-analyses. It characterizes the relationships of eGFR and albuminuria or proteinuria and prognosis for all-cause mortality and cardiovascular mortality.CrossRef •• Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073–2081. This landmark study involved a very large collection of databases and meta-analyses. It characterizes the relationships of eGFR and albuminuria or proteinuria and prognosis for all-cause mortality and cardiovascular mortality.CrossRef
18.
go back to reference Kalaitzidis RG, Bakris GL: Serum creatinine vs albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol 2010 (Epub ahead of print). Kalaitzidis RG, Bakris GL: Serum creatinine vs albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol 2010 (Epub ahead of print).
19.
go back to reference Perkins BA, Ficociello LH, Silva KH, et al.: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285–2293.CrossRefPubMed Perkins BA, Ficociello LH, Silva KH, et al.: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285–2293.CrossRefPubMed
20.
go back to reference Steinke JM, Sinaiko AR, Kramer MS, et al.; International Diabetic Nephropathy Study Group: The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005, 54:2164–2171.CrossRefPubMed Steinke JM, Sinaiko AR, Kramer MS, et al.; International Diabetic Nephropathy Study Group: The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005, 54:2164–2171.CrossRefPubMed
21.
go back to reference • Glassock R: Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010, 31:462–465. This article forms part of a “debate” regarding the significance of microalbuminuria as a surrogate end point in prospective clinical trials.CrossRefPubMed • Glassock R: Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010, 31:462–465. This article forms part of a “debate” regarding the significance of microalbuminuria as a surrogate end point in prospective clinical trials.CrossRefPubMed
22.
go back to reference Bello AK, de Zeeuw D, El Nahas M, et al.: Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant 2007, 22:1619–1627.CrossRefPubMed Bello AK, de Zeeuw D, El Nahas M, et al.: Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant 2007, 22:1619–1627.CrossRefPubMed
23.
go back to reference Vlassara H, Torreggiani M, Post JB, et al.: Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int Suppl 2009, 114:S3–S11.CrossRefPubMed Vlassara H, Torreggiani M, Post JB, et al.: Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int Suppl 2009, 114:S3–S11.CrossRefPubMed
24.
go back to reference Perkins BA, Ficociello LH, Roshan B, et al.: In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010, 77:57–64.CrossRefPubMed Perkins BA, Ficociello LH, Roshan B, et al.: In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010, 77:57–64.CrossRefPubMed
25.
go back to reference Mauer M, Zinman B, Gardiner R, et al.: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40–51.CrossRefPubMed Mauer M, Zinman B, Gardiner R, et al.: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40–51.CrossRefPubMed
26.
go back to reference Ito H, Takeuchi Y, Ishida H, et al.: High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrol Dial Transplant 2010, 25:1161–1167.CrossRefPubMed Ito H, Takeuchi Y, Ishida H, et al.: High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrol Dial Transplant 2010, 25:1161–1167.CrossRefPubMed
27.
go back to reference • Bakris GL, Sarafidis PA, Weir MR, et al.; ACCOMPLISH Trial Investigators: Renal outcomes with different fixed dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised clinical trial. Lancet 2010, 375:1173–1181. This seminal clinical trial showed that a change in microalbuminuria can be dissociated from renal outcomes with fixed-dose combined therapy in high-risk patients.CrossRefPubMed • Bakris GL, Sarafidis PA, Weir MR, et al.; ACCOMPLISH Trial Investigators: Renal outcomes with different fixed dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised clinical trial. Lancet 2010, 375:1173–1181. This seminal clinical trial showed that a change in microalbuminuria can be dissociated from renal outcomes with fixed-dose combined therapy in high-risk patients.CrossRefPubMed
28.
go back to reference Lorenzo V, Saracho R, Zamora J, et al.: Similar renal decline in diabetic and non-diabetic patients with comparable degrees of albuminuria. Nephrol Dial Transplant 2010, 25:835–841.CrossRefPubMed Lorenzo V, Saracho R, Zamora J, et al.: Similar renal decline in diabetic and non-diabetic patients with comparable degrees of albuminuria. Nephrol Dial Transplant 2010, 25:835–841.CrossRefPubMed
29.
go back to reference • de Jong P, Gansevoort RT: Albuminuria in non-primary renal disease: risk marker rather than risk factor. Nephrol Dial Transplant 2010, 25:656–658. This article provides a nice critical review of the status of microalbuminuria as a risk factor or risk marker.CrossRefPubMed • de Jong P, Gansevoort RT: Albuminuria in non-primary renal disease: risk marker rather than risk factor. Nephrol Dial Transplant 2010, 25:656–658. This article provides a nice critical review of the status of microalbuminuria as a risk factor or risk marker.CrossRefPubMed
30.
go back to reference Choi SW, Yun WJ, Kim HY et al.: Association between albuminuria, carotid atherosclerosis, arterial stiffness and peripheral artery disease in Korean type 2 diabetic patients. Kidney Blood Press Res 2010, 33:111–118.CrossRefPubMed Choi SW, Yun WJ, Kim HY et al.: Association between albuminuria, carotid atherosclerosis, arterial stiffness and peripheral artery disease in Korean type 2 diabetic patients. Kidney Blood Press Res 2010, 33:111–118.CrossRefPubMed
31.
go back to reference Solbu MD, Jenssen TG, Eriksen BO, Toft I: Changes in insulin sensitivity, renal function and markers of endothelial dysfunction in hypertension—the impact of microalbuminuria: a 13 year follow-up study. Metabolism 2009, 58:408–415.CrossRefPubMed Solbu MD, Jenssen TG, Eriksen BO, Toft I: Changes in insulin sensitivity, renal function and markers of endothelial dysfunction in hypertension—the impact of microalbuminuria: a 13 year follow-up study. Metabolism 2009, 58:408–415.CrossRefPubMed
32.
go back to reference Silva AM, Schaan BD, Signori LU, et al.: Microalbuminuria is associated with impaired arterial and venous endothelium dependent vasodilation in patients with type 2 diabetes. J Endocrinol Invest 2010 (Epub ahead of print). Silva AM, Schaan BD, Signori LU, et al.: Microalbuminuria is associated with impaired arterial and venous endothelium dependent vasodilation in patients with type 2 diabetes. J Endocrinol Invest 2010 (Epub ahead of print).
33.
go back to reference Foster MC, Keyes MJ, Larson MG, et al.: Relations of measures of endothelial function and kidney disease: the Framingham Heart Study. Am J Kidney Dis 2008, 52:859–867.CrossRefPubMed Foster MC, Keyes MJ, Larson MG, et al.: Relations of measures of endothelial function and kidney disease: the Framingham Heart Study. Am J Kidney Dis 2008, 52:859–867.CrossRefPubMed
34.
go back to reference Rifkin DE, Katz R, Chonchoi M, et al.: Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant 2010, 25:1560–1567.CrossRefPubMed Rifkin DE, Katz R, Chonchoi M, et al.: Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant 2010, 25:1560–1567.CrossRefPubMed
35.
go back to reference Bielby J, Divitini ML, Knuiman MW, et al.: Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population. Clin Chem 2010, 56:799–804.CrossRef Bielby J, Divitini ML, Knuiman MW, et al.: Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population. Clin Chem 2010, 56:799–804.CrossRef
Metadata
Title
Is the Presence of Microalbuminuria a Relevant Marker of Kidney Disease?
Author
Richard J. Glassock
Publication date
01-10-2010
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 5/2010
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-010-0133-3

Other articles of this Issue 5/2010

Current Hypertension Reports 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine